High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine

Ejemplares similares

• Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
  por: Dillman, Robert O, et al.
  Publicado: (2019)
• Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
  por: Dillman, Robert O., et al.
  Publicado: (2018)
• Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment
  por: Dillman, Robert O., et al.
  Publicado: (2015)
• Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
  por: Dillman, Robert O, et al.
  Publicado: (2015)
• Phase III randomized, double-blinded, placebo-controlled multicenter trial of melapuldencil-t: autologous dendritic cells loaded with irradiated autologous tumor cells (dc-tc) in gm-csf in patients with metastatic melanoma
  por: Dillman, Robert, et al.
  Publicado: (2014)